Activest Wealth Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Activest Wealth Management’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-334	Closed	-$374	–	1154
2025 Q2	$374	Hold	334	–	–	﹤0.01%	906
2025 Q1	$421	Hold	334	–	–	﹤0.01%	867
2024 Q4	$758	Hold	334	–	–	﹤0.01%	485
2024 Q3	$1.15K	Sell	334 -138	-29%	-$651	﹤0.01%	454
2024 Q2	$2.4K	Buy	+472	New	+$3.54K	﹤0.01%	389

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.53B AUM 17.43% 1-Year Est. Return

Activest Wealth Management's BCLI Position: Q3 2025 in Review

Activest Wealth Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 334 shares — an estimated $374 sold.

Activest Wealth Management first reported a position in BCLI in Q2 2024 and held it in 5 quarters. The position peaked at $2.4K in Q2 2024. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

Activest Wealth Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
Activest Wealth Management sold 334 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $374.
Activest Wealth Management first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2024 and held it in 5 quarters.
Activest Wealth Management's BRAINSTORM CELL THERAPUTC position peaked at $2.4K in Q2 2024.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Activest Wealth Management's 13F filing for Q3 2025, filed 3 Nov 2025.